These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 2203486

  • 1. Prolonged blood pressure reduction by orally active renin inhibitor RO 42-5892 in essential hypertension.
    van den Meiracker AH, Admiraal PJ, Man in 't Veld AJ, Derkx FH, Ritsema van Eck HJ, Mulder P, van Brummelen P, Schalekamp MA.
    BMJ; 1990 Jul 28; 301(6745):205-10. PubMed ID: 2203486
    [Abstract] [Full Text] [Related]

  • 2. Comparison of blood pressure and angiotensin responses to the renin inhibitor Ro 42-5892 and the angiotensin converting enzyme inhibitor enalapril in essential hypertension.
    van den Meiracker AH, Admiraal PJ, Derkx FH, Kleinbloesem C, Man in 't Veld AJ, van Brummelen P, Mulder P, Schalekamp MA.
    J Hypertens; 1993 Aug 28; 11(8):831-8. PubMed ID: 8228207
    [Abstract] [Full Text] [Related]

  • 3. Effects of an orally active renin inhibitor, Ro 42-5892, in patients with essential hypertension.
    Kobrin I, Viskoper RJ, Laszt A, Bock J, Weber C, Charlon V.
    Am J Hypertens; 1993 May 28; 6(5 Pt 1):349-56. PubMed ID: 8512659
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.
    O'Brien E, Barton J, Nussberger J, Mulcahy D, Jensen C, Dicker P, Stanton A.
    Hypertension; 2007 Feb 28; 49(2):276-84. PubMed ID: 17159081
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Antihypertensive effect of a non-peptide angiotensin II receptor antagonist, MK954, in patients with essential hypertension].
    Hagino T, Abe K, Tsunoda K, Yoshinaga K.
    Nihon Jinzo Gakkai Shi; 1992 Feb 28; 34(2):133-40. PubMed ID: 1588765
    [Abstract] [Full Text] [Related]

  • 12. Effect of the renin response during renin inhibition: oral Ro 42-5892 in normal humans.
    Camenzind E, Nussberger J, Juillerat L, Munafo A, Fischli W, Coassolo P, van Brummelen P, Kleinbloesem CH, Waeber B, Brunner HR.
    J Cardiovasc Pharmacol; 1991 Sep 28; 18(3):299-307. PubMed ID: 1720828
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Long-term antihypertensive effects of aliskiren, a direct renin inhibitor, in chronic hemodialysis patients.
    Ishimitsu T, Ohta S, Ohno E, Takahashi T, Numabe A, Okamura A, Ohba S, Hashimoto A, Matsuoka H.
    Ther Apher Dial; 2013 Oct 28; 17(5):524-31. PubMed ID: 24107281
    [Abstract] [Full Text] [Related]

  • 16. Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response?
    van den Meiracker AH, Man in 't Veld AJ, Admiraal PJ, Ritsema van Eck HJ, Boomsma F, Derkx FH, Schalekamp MA.
    J Hypertens; 1992 Aug 28; 10(8):803-12. PubMed ID: 1325513
    [Abstract] [Full Text] [Related]

  • 17. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients.
    Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP.
    Circulation; 2005 Mar 01; 111(8):1012-8. PubMed ID: 15723979
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. SC-52458, an orally active angiotensin II-receptor antagonist: inhibition of blood pressure response to angiotensin II challenges and pharmacokinetics in normal volunteers.
    Hagmann M, Nussberger J, Naudin RB, Burns TS, Karim A, Waeber B, Brunner HR.
    J Cardiovasc Pharmacol; 1997 Apr 01; 29(4):444-50. PubMed ID: 9156352
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.